The head offices of Valeant Pharmaceuticals  in Laval, Quebec. The Canadian-based company said Allergan’s refusal to enter talks left it with no option but to go hostile in the battle for control of its US rival. Photograph: Christinne Muschi/Reuters

Valeant Pharmaceuticals is preparing to take its bid for Allergan direct to shareholders after its latest $53 billion offer was rejected by the mak(...)

Pfizer’s plan to move its domicile to Britain by acquiring AstraZeneca would lower its taxes. Photograph: getty images

Rumours about a massive healthcare deal were circulating in industry circles, months before Pfizer disclosed its $100 billion pursuit of Britain’s Ast(...)

The pace of acquisition at the formerly stolid generics player has been bewildering in the 22 months since Watson acquired Actavis.

As the dust settles on Actavis’s latest megamerger, the Dublin-headquartered but US-based group managed to win its first post-M&A battle – (...)

Ryanair repurchased 109,000 shares yesterday as part of its plans to return €1 billion in capital to shareholders by way of a combination of share buybacks and dividends.  Photograph: Rui Vieira/PA Wire

US stocks fluctuated, with the Standard & Poor’s 500 Index close to a record, as a $25 billion deal to acquire Forest Labo(...)

Forest Laboratories employs 320 people in Ireland. Dublin-headquartered Actavis, the world’s second-largest generic-drug maker by market value, is to buy Forest Labs for $25 billion. Photo: Jim Peppler

Actavis, the world’s second-largest generic-drug maker by market value, is to buy Forest Laboratories in a cash and stock deal valued at about(...)

Elan chief executive Kelly Martin, a former  Merrill Lynch banker, took the helm in 2003, drastically paring down the company and opting to focus on the development of multiple sclerosis drug Tysabri.  Photograph: Alan Betson

The sale of Elan to Perrigo marks the end of a rollercoaster ride for the Irish drugmaker, which has fended off three takeover bids by private equity (...)

There are few synergies in some of the latest transactions in the pharma sector.

The age of the blockbuster deal may have passed but recent mergers and acquisitions activity in the pharma sector could still have a noticeable impact(...)

Generic drugmaker Actavis, which has been the subject of takeover speculation, plans to buy specialty pharmaceutical company Warner Chil- cott (...)